Demonstrated scientific leadership with new clinical data presented at major congresses, including positive phase II results for nemolizumab in children with moderate-to-severe atopic dermatitis and new data strengthening the Injectable Aesthetics portfolio to address latest patient needs, with pioneering research on menopause-related skin changes.

Strengthened financial profile and shareholder returnsthrough share repurchases, a dividend payment, and a successful Eurobond placement of 500 million EUR in March to fully repay the Term Loan, following the earlier replacement of the Revolving Credit Facility.

Completed the transition to a free-float dominated shareholder base, following the full divestment by the EQT-led consortium of investors, marking the largest fully monetized capital gain from a single private equity fund.

Confirming 2026 full-year guidance, with net sales growth of 17-20% year-on-year at constant currency and a Core EBITD
=*=*=*=*=*=
当前为第2/27页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页